1. Clear MoA.
NGF is released upon injury and causes pain by activating its receptor TrkA on nociceptors and mast cells, leading to transmission of pain signals from the periphery to the spinal cord and brain via the dorsal ganglion. And the efficacies of anti-NGF have been validated clinically in a variety of pain conditions
2. Wide range of indications：Pain.
3. Excellent Phase I Data
(1). No dose-dependent AEs have been identified in Phase I.
(2). NGF mAb is expected to be administered every 8 weeks based on its PK profiles.
4. Global competitiveness.
The analgesic effect of NGF mAb is comparable to that of morphine, but it is not addictive.
The RPOA risk can be reduced by selecting cancer-related indications and excluding OA patients.
1. Asset type: Humanized NGF mAb
2. Indication: Cancer pain, chemotherapy-induced neuropathic pain, Kashin-Beck disease, diabetic neuralgia, interstitial cystitis, chronic low back pain.
3. Research phase: Phase Ⅰ/Ⅱa
4. Research progress：
1) Complete the first human trial.
2) Complete the single-dose escalation trial.
3) Complete the PK and safety trial:
NGF mAb is expected to be administered every 8 weeks based on its PK profiles.
No dose-dependent AEs have been identified in Phase I.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.